5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p id="d601723e265">The Clinical Assessment Interview for Negative Symptoms (CAINS) was designed in accordance with the recent theory and research in social affective neuroscience and to address the psychometric and conceptual limitations of other instruments assessing negative symptoms. The present study aimed to provide a large-scale validation of the CAINS in China and examine its applicability and validity evidence across the schizophrenia spectrum. Using confirmatory factor analysis, our results replicated the original findings in the US development samples that the CAINS possesses a stable 2-factor structure, namely “motivation/pleasure” and “expression”. We also found significant correlations between the CAINS and other negative symptom measures. The CAINS demonstrated good discriminant validity in differentiating negative symptoms in people with schizophrenia, nonpsychotic first-degree relatives and people with social anhedonia. People with schizophrenia exhibited significantly higher CAINS subscale scores than first-degree relatives and healthy controls. In addition, first-degree relatives had higher “motivation/pleasure” scores than healthy controls. The “motivation/pleasure” subscale scores of individuals with social anhedonia were also significantly higher than healthy controls. </p>

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Rethinking schizophrenia.

          How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world's population. After a century of studying schizophrenia, the cause of the disorder remains unknown. Treatments, especially pharmacological treatments, have been in wide use for nearly half a century, yet there is little evidence that these treatments have substantially improved outcomes for most people with schizophrenia. These current unsatisfactory outcomes may change as we approach schizophrenia as a neurodevelopmental disorder with psychosis as a late, potentially preventable stage of the illness. This 'rethinking' of schizophrenia as a neurodevelopmental disorder, which is profoundly different from the way we have seen this illness for the past century, yields new hope for prevention and cure over the next two decades.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The structure of negative symptoms within schizophrenia: implications for assessment.

            This review examines the structural validity of negative symptoms focusing on 2 questions: (1) Do negative symptoms represent a domain separate from other symptoms in schizophrenia? and (2) Within negative symptoms, is there a structure that suggests multidimensionality? Results from exploratory and confirmatory factor analytic studies are examined to address these questions. Across studies and symptom instruments, negative symptoms appear to consistently emerge as a factor separate from other dimensions of the illness in schizophrenia. Whether 2-, 3-, or 5-factor models are identified, negative symptoms consistently load on a factor separate from positive symptoms, affective symptoms of depression or anxiety, and symptoms of disorganization. Focusing on negative symptoms themselves, factor analytic findings suggest that this construct is multidimensional with at least 2 factors (involving diminished expression and anhedonia-asociality). Although these factors were replicable, serious limitations were noted in this literature. Thus, 2- (or even 3- or 5-) factor models of negative symptoms should not be considered definitive, but rather all converge to support the general conclusion of the multidimensionality of negative symptoms. The later findings indicate the importance of employing assessments that provide adequate coverage of the broad domain of negative symptoms. Importantly, caution is noted in the interpretability of findings based on existing instruments, and implications for future assessment are discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.

              The ultra high-risk (UHR) criteria were introduced to prospectively identify patients at high risk of psychotic disorder. Although the short-term outcome of UHR patients has been well researched, the long-term outcome is not known.
                Bookmark

                Author and article information

                Journal
                Schizophrenia Bulletin
                Oxford University Press (OUP)
                0586-7614
                1745-1701
                November 2018
                October 15 2018
                February 20 2018
                November 2018
                October 15 2018
                February 20 2018
                : 44
                : suppl_2
                : S547-S555
                Affiliations
                [1 ]Neuropsychology and Applied Cognitive Neuroscience Laboratory, CAS Key Laboratory of Mental Health, Institute of Psychology, Beijing, China
                [2 ]Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
                [3 ]North China Electric Power University, Beijing, China
                [4 ]Castle Peak Hospital, Hong Kong Special Administrative Region, China
                [5 ]Peking University Sixth Hospital, Beijing, China
                [6 ]Peking University Institute of Mental Health, Beijing, China
                [7 ]Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China
                [8 ]Haidian District Mental Health Prevent-Treatment Hospital, Beijing, China
                [9 ]Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, China
                [10 ]Department of Psychology, University of California, Berkeley, CA
                Article
                10.1093/schbul/sby013
                6188520
                29471331
                629db708-62ed-4272-9442-70fc9710765c
                © 2018

                https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

                History

                Comments

                Comment on this article